GlassScriptPhysician profile
Jong-Hyun Nam
NPI 1205805843
$7,436.00
in general payments reported to CMS, 2019-2025
35 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $424 · 2021: $1,150 · 2022: $1,174 · 2023: $1,450 · 2024: $1,169 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,677 · Education: $91.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,676.89 |
| Education | $91.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,512.73 | 2019-2025 | |
| Janssen Biotech, INC. | $908.36 | 2019-2025 | Stelara, Simponi Aria, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $569.24 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $384.06 | 2021-2024 | Zeposia |
| Pfizer INC. | $378.97 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.94 | 2019-2025 | Xifaxan, Relistor |
| Ironwood Pharmaceuticals, INC | $236.57 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $210.38 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $195.70 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $158.69 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $147.08 | 2020-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $124.47 | 2024-2025 | Voquezna |
| Thd America, INC. | $124.23 | 2022 | |
| Ucb, INC. | $121.92 | 2019-2020 | |
| Lilly USA, LLC | $118.79 | 2024-2025 | Omvoh |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $106.41 | 2019-2024 | Dificid, Zinplava |
| Redhill Biopharma INC. | $104.14 | 2020-2021 | |
| Fujifilm Healthcare Americas Corporation | $101.24 | 2021-2022 | |
| Genzyme Corporation | $95.43 | 2022-2025 | |
| Celltrion USA INC. | $77.75 | 2023-2025 | Zymfentra, Yuflyma, Vegzelma |
| Nestle Healthcare Nutrition INC. | $46.50 | 2022-2023 | |
| Allergan, INC. | $44.33 | 2019-2020 | |
| Sandoz INC. | $41.40 | 2023 | Hyrimoz |
| Ardelyx, INC. | $40.95 | 2023-2024 | Ibsrela |
| Boston Scientific Corporation | $36.10 | 2020-2023 | Endoarmor |
| Daiichi Sankyo INC. | $32.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.95 | 2021 | |
| Qol Medical, LLC | $21.54 | 2025 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.76 | 2024 | Cyltezo |
| Intra-Sana Laboratories | $16.75 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Concordia Pharmaceuticals INC. | $15.18 | 2019 | |
| Erbe USA INC | $15.00 | 2023 | Erbe Clever Cap |
| Aimmune Therapeutics, INC. | $14.15 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $13.80 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jong-Hyun Nam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.